Immunology
FDA accepts Intercept’s resubmitted NDA for obeticholic acid
Nonalcoholic steatohepatitis (NASH) is described as a subgroup of nonalcoholic fatty liver disease (NAFLD), where excessive fat buildup is accompanied…
Study finds higher suicide rate among patients with severe health conditions
As the stigma surrounding mental health continues to diminish, health professionals have begun to shed light on the risk of…
Hutchmed completes subject enrolment in ITP therapy trial
Hutchmed has completed participant enrolment in a Phase III ESLIM-01 clinical trial of sovleplenib for primary immune thrombocytopenia (ITP), in…
Petition to update US alcohol warning label could prevent many cancer cases
In October 2020, eight public health advocacy groups filed a petition urging the US Treasury Department’s Alcohol and Tobacco Tax…
Systemic lupus erythematosus: major drug trials to watch in 2022 and 2023
Systemic lupus erythematosus (SLE), the most common type of lupus, is an autoimmune disease that causes the body to attack…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Pipeline agents to improve the management of pruritus in atopic dermatitis
Anti-itch agents are becoming more prominent in the atopic dermatitis (AD) therapeutic space with multiple new product candidates in the…
Kezar to commence Phase IIa autoimmune hepatitis therapy trial
Kezar Life Sciences has announced plans to commence the Phase IIa PORTOLA clinical trial (KZR-616-208) of zetomipzomib to treat autoimmune…
EADV 2022: Dupixent shows sustained efficacy across anatomical regions in children
Sanofi and Regeneron presented analyses from the LIBERTY AD PRESCHOOL (NCT03346434) study of interleukin (IL)-4/13 inhibitor, Dupixent (dupilumab), at the…
Pipeline Moves: Novartis completes Phase II Sjögren’s syndrome trial, advancement prospects jump
This week on Pipeline Moves, we look into the Novartis completion of a Phase II trial in Sjögren's syndrome. We…
Pipeline Moves: Nektar terminates Phase I/II cancer trial, further study shot in seven indications drop
In this week’s edition of Pipeline Moves, the Clinical Trials Arena team studies Nektar Therapeutics’s termination of a Phase I/II…